AWP
RXRX icon

Ascent Wealth Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

Ascent Wealth Partners’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$86.2K Buy
28,081
+2,974
+12% +$11.5K 0.01% 187
2025
Q4 		$103K Buy
25,107
+3,336
+15% +$16.5K 0.01% 181
2025
Q3 		$106K Buy
21,771
+4,275
+24% +$22.5K 0.01% 179
2025
Q2 		$88.5K Buy
+17,496
New +$86K 0.01% 171

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ascent Wealth Partners's RXRX Position: Q1 2026 in Review

Ascent Wealth Partners increased its Recursion Pharmaceuticals (RXRX) stake by 12% in Q1 2026, buying an estimated $11.5K and bringing the position to 28,081 shares worth $86.2K. The position accounts for 0.01% of the portfolio, ranked #187.

Ascent Wealth Partners first reported a position in RXRX in Q2 2025 and has held it in 4 quarters since. The position peaked at $106K in Q3 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Ascent Wealth Partners held 28,081 shares of Recursion Pharmaceuticals worth $86.2K as of Q1 2026.
  • Ascent Wealth Partners bought 2,974 Recursion Pharmaceuticals shares in Q1 2026, an estimated $11.5K.
  • Recursion Pharmaceuticals made up 0.01% of Ascent Wealth Partners's portfolio in Q1 2026, its #187 holding.
  • Ascent Wealth Partners first reported a position in Recursion Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Ascent Wealth Partners's Recursion Pharmaceuticals position peaked at $106K in Q3 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Ascent Wealth Partners's 13F filing for Q1 2026, filed 6 May 2026.